Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
1.230
-0.040 (-3.15%)
Aug 24, 2026, 11:52 AM EDT - Market open
Biodexa Pharmaceuticals Balance Sheet
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8.53 | 1.67 | 5.97 | 2.84 | 10.06 |
Cash & Short-Term Investments | 8.53 | 1.67 | 5.97 | 2.84 | 10.06 |
Cash Growth | 411.32% | -72.05% | 110.54% | -71.80% | 33.28% |
Accounts Receivable | 0.04 | 0.01 | - | 0.33 | 0.03 |
Other Receivables | 0.19 | 0.7 | 0.7 | 1.15 | 1.06 |
Receivables | 0.22 | 0.72 | 0.7 | 1.48 | 1.1 |
Prepaid Expenses | 3.69 | 6.43 | 0.36 | 0.38 | 0.61 |
Total Current Assets | 12.44 | 8.81 | 7.03 | 4.69 | 11.76 |
Property, Plant & Equipment | 0.09 | 0.32 | 0.57 | 0.83 | 1.15 |
Other Intangible Assets | 5.65 | 5.65 | 2.94 | 0.01 | - |
Total Assets | 18.18 | 14.78 | 10.54 | 5.53 | 12.91 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.1 | 0.71 | 0.31 | 0.34 | 0.49 |
Accrued Expenses | 1.86 | 1.27 | 0.86 | 0.82 | 0.55 |
Short-Term Debt | - | 0.43 | - | - | - |
Current Portion of Leases | 0.06 | 0.18 | 0.17 | 0.16 | 0.15 |
Current Income Taxes Payable | 0.05 | 0.05 | 0.06 | 0.08 | 0.06 |
Current Unearned Revenue | 0.57 | 1.47 | - | 0.2 | - |
Other Current Liabilities | 3.5 | 0.93 | 4.17 | 0.31 | 0.61 |
Total Current Liabilities | 6.13 | 5.03 | 5.57 | 1.9 | 1.84 |
Long-Term Leases | - | 0.12 | 0.3 | 0.46 | 0.62 |
Other Long-Term Liabilities | 0.65 | 1.31 | - | - | - |
Total Liabilities | 6.77 | 6.46 | 5.86 | 2.36 | 2.46 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.23 | 0.33 | 1.19 | 0.11 | 0.1 |
Additional Paid-In Capital | 98.92 | 93.12 | 86.73 | 83.67 | 83.43 |
Retained Earnings | -155.81 | -150.42 | -144.77 | -135.34 | -127.8 |
Comprehensive Income & Other | 68.06 | 65.29 | 61.52 | 54.72 | 54.72 |
Shareholders' Equity | 11.41 | 8.32 | 4.68 | 3.16 | 10.45 |
Total Liabilities & Equity | 18.18 | 14.78 | 10.54 | 5.53 | 12.91 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.06 | 0.73 | 0.46 | 0.62 | 0.77 |
Net Cash (Debt) | 8.47 | 0.94 | 5.51 | 2.21 | 9.29 |
Net Cash Growth | 799.47% | -82.89% | 148.96% | -76.19% | 27.52% |
Net Cash Per Share | 77.22 | - | - | - | - |
Filing Date Shares Outstanding | 0.65 | 0.05 | - | - | - |
Total Common Shares Outstanding | 0.45 | 0.01 | - | - | - |
Working Capital | 6.31 | 3.78 | 1.46 | 2.79 | 9.92 |
Book Value Per Share | 25.25 | 622.35 | - | - | - |
Tangible Book Value | 5.76 | 2.68 | 1.74 | 3.16 | 10.45 |
Tangible Book Value Per Share | 12.75 | 200.12 | - | - | - |
Machinery | 0.16 | 0.77 | 1.52 | 1.59 | 1.87 |
Leasehold Improvements | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |